Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course radiotherapy combined with surufatinib and sintilimab for relapsed or refractory advanced solid tumors
ChiCTR2200062791Phase 2Not yet recruiting
- Sponsor
- Tongji Medical College
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib and sintilimab in Nonhematologic neoplasms, biliary cancer, gastric cancer (GC) and 1 more, sponsored by Tongji Medical College. Primary endpoint: Progression-free survival. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
surufatinibsintilimab
03
Conditions
Nonhematologic neoplasmsbiliary cancergastric cancer (GC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2200062791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062791.